New Data Evaluating HYMOVIS® Effects on Cartilage Volume and Type II Collagen Turnover at OARSI World Congress Meeting

Poster Title: “Hyaluronan Derivative Hymovis® Increases Cartilage Volume and Type II Collagen Turnover in Osteoarthritis Knee:
Data from MOKHA (MRI, BiOmarkers, Knee, Hymovis®, OsteoArthritis) Study”

Abano Terme, Italy, April 25, 2018 – Fidia Farmaceutici, a world leader in the research, development and manufacturing of hyaluronic acid (HA)-based products and its wholly owned subsidiary, Fidia Pharma USA Inc., announce that new data will be presented at the Osteoarthritis Research Society International (OARSI) World Congress Meeting in Liverpool, U.K., April 26-29.

The pilot study “MOKHA,” coordinated by Fidia Farmaceutici, which involved eight sites in France and Belgium, aimed to explore the potential structural modifying effect of HYMOVIS®, an HA viscosupplement, in patients suffering from symptomatic knee osteoarthritis (OA) using a combination of clinical outcomes and objective measurements including biological and MRI-based imaging markers.

This open, multicenter, prospective study on 46 patients showed that HYMOVIS® significantly enhanced type II collagen turnover as suggested by the increase of Coll2-1 (p<0.001) and PIINAP (p<0.001) soluble biomarkers and by the decrease over time of the ratios Coll2-1/PIIANP and CTX-II/PIIANP (p<0.005). Cartilage volume and thickness enhancement was observed by MRI in some knee compartments (p<0.05). Furthermore, WORMS effusion (Whole-Organ Magnetic Resonance Imaging Score), an indicator of synovitis, significantly decreased (p<0.016).

• Potential beneficial effect of HYMOVIS® on pain and function
• Structural modifying effect in knee OA with HYMOVIS®


Find out more about Fidia’s product portfolio:

Go to the website


Fidia Farmaceutici has a specific module dedicated to Pharmaco-Vigilance in order to promptly reporting of suspected adverse reactions. If you suspect that you have had an adverse reaction while taking one of our products or you have found defects

Key Business Areas

Fidia operates in numerous therapeutic areas, providing specific, innovative treatments for commonly occurring pathologies with major socio-economic impact, namely:

- joint care
- ophthalmology
- active wound care
- neuroscience
- aesthetic medicine